Sickle Cell Care Management and Treatment Education:
HB 333 creates a new section of Florida Statutes requiring certain licensed health care professionals to complete a one-time, 2-hour continuing education course on sickle cell disease care management and treatment education as part of their first licensure or certification renewal. The requirement applies to professionals licensed or certified under chapters 458, 459, and part I of chapter 464, which generally covers physicians, osteopathic physicians, and nurses. The course must cover sickle cell disease and sickle cell trait, including evidence-based treatment protocols, patient and family education, comprehensive evaluations, psychosocial care, genetic counseling, and pain management.
The bill also allows boards to approve equivalent courses, lets the required hour count toward overall continuing education in many cases, and permits licensees with multiple covered licenses to use one course completion to satisfy the requirement for all applicable licenses. Failure to comply would be grounds for disciplinary action under the relevant practice acts and existing disciplinary statute, and the licensee would still have to complete the course. The act would take effect July 1, 2025.
HB 333 would add a new continuing education mandate to Florida’s professional licensing framework by creating s. 456.0311, F.S. It would affect the licensing and renewal requirements for physicians, osteopathic physicians, and nurses, and would authorize the relevant boards to adopt rules and approve equivalent courses. The bill also ties noncompliance to disciplinary authority under existing law, expanding the enforcement tools available to licensing boards.
The available context suggests generally favorable treatment of the bill in concept, as it advanced far enough to be considered in committee, but it ultimately did not become law. There are no recorded votes or committee transcript excerpts in the provided materials, so there is no direct evidence of floor debate or formal opposition in the record here. Its final status—dying in the Health Professions & Programs Subcommittee—indicates it did not secure enough support or time to move forward.
The main potential points of contention are the added continuing education burden on licensed health care professionals and the use of disciplinary consequences for noncompliance. Some stakeholders may view the mandate as a modest, targeted education requirement that improves care for patients with sickle cell disease, while others may object to another renewal condition, especially for professionals already subject to substantial continuing education obligations. The bill’s requirement that boards approve the course content and its application across multiple licensing categories could also raise implementation questions, but no specific objections are documented in the provided record.